Stock listing
NASDAQ:CRVS Corvus Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Corvus Pharmaceuticals, Inc.
Follow Corvus Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CRVS
$9.67 USD -0.52 (-5.1%)
Close on Nov 20, 2026
- Day range
- $9.56 – $10.03 USDNov 20, 2026
- Volume
- 927,517 sharesNov 20, 2026
- Market cap
- $815.7M USDAt the close on Nov 20, 2026 · price × 84.35M shares outstanding
- 52-week range
- $6.39 – $26.95 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $11.86M USDMedian day 950,784 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRVS · Home | $9.67 USD | -0.52 (-5.1%) | 927,517 | $9.84 | $10.03 | $9.555 | $10.19 | Close on Nov 20, 2026 |
| Frankfurt:C17 | €8.804 EUR | -0.34 (-3.7%) | — | €8.694 | €8.804 | €8.694 | €9.144 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRVS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $9.67 | -0.52 | -5.1% | $9.84 | $10.03 | $9.555 | 927,517 | |
| $10.19 | +0.02 | +0.2% | $10.16 | $10.48 | $9.945 | 987,178 | |
| $10.17 | -0.43 | -4.1% | $10.84 | $10.84 | $10.10 | 925,795 | |
| $10.60 | -0.04 | -0.4% | $10.78 | $11.05 | $10.43 | 751,024 | |
| $10.64 | +0.02 | +0.2% | $10.62 | $10.76 | $10.24 | 620,420 | |
| $10.62 | -0.85 | -7.4% | $11.20 | $11.41 | $10.59 | 1,021,016 | |
| $11.47 | +0.10 | +0.9% | $11.32 | $11.76 | $11.25 | 822,119 | |
| $11.37 | +0.02 | +0.2% | $11.35 | $11.78 | $11.09 | 950,784 | |
| $11.35 | +0.81 | +7.7% | $10.71 | $11.63 | $10.49 | 1,271,856 | |
| $10.54 | +0.81 | +8.3% | $10.65 | $10.96 | $9.64 | 1,257,477 | |
| $9.73 | -0.84 | -7.9% | $10.44 | $10.55 | $9.69 | 1,145,111 | |
| $10.57 | +0.74 | +7.5% | $10.29 | $10.59 | $9.765 | 1,271,222 | |
| $9.83 | +0.13 | +1.3% | $9.73 | $10.06 | $9.73 | 776,001 | |
| $9.70 | -0.33 | -3.3% | $10.10 | $10.21 | $9.60 | 614,265 | |
| $10.03 | -0.20 | -2.0% | $10.09 | $10.37 | $9.78 | 845,085 | |
| $10.23 | -0.29 | -2.8% | $10.57 | $10.74 | $10.18 | 852,138 | |
| $10.52 | -0.02 | -0.2% | $10.40 | $10.70 | $10.29 | 911,663 | |
| $10.54 | +0.09 | +0.9% | $10.49 | $10.80 | $10.31 | 1,132,702 | |
| $10.45 | -0.08 | -0.8% | $10.54 | $10.61 | $10.35 | 981,128 | |
| $10.53 | -0.12 | -1.1% | $10.58 | $10.65 | $10.08 | 933,657 | |
| $10.65 | +0.60 | +6.0% | $9.92 | $10.68 | $9.85 | 1,080,556 | |
| $10.05 | -0.18 | -1.8% | $10.25 | $10.59 | $10.00 | 868,812 | |
| $10.23 | +0.58 | +6.0% | $9.67 | $10.33 | $9.65 | 1,066,930 | |
| $9.65 | +0.13 | +1.4% | $9.73 | $10.00 | $9.50 | 820,335 | |
| $9.52 | -0.33 | -3.4% | $9.81 | $10.12 | $9.433 | 1,035,600 | |
| $9.85 | +0.47 | +5.0% | $9.49 | $10.07 | $9.36 | 1,000,200 | |
| $9.38 | -0.03 | -0.3% | $9.31 | $9.50 | $9.21 | 976,800 | |
| $9.41 | -0.64 | -6.4% | $9.99 | $10.03 | $9.32 | 1,685,600 | |
| $10.05 | -0.47 | -4.5% | $10.43 | $10.52 | $10.02 | 719,700 | |
| $10.52 | +0.31 | +3.0% | $10.21 | $10.71 | $10.08 | 1,032,300 | |
| $10.21 | -0.20 | -1.9% | $10.15 | $10.31 | $9.82 | 1,881,000 | |
| $10.41 | -0.15 | -1.4% | $10.25 | $10.65 | $10.25 | 1,157,100 | |
| $10.56 | -0.18 | -1.7% | $10.75 | $10.96 | $10.20 | 1,441,100 | |
| $10.74 | -0.16 | -1.5% | $10.88 | $11.15 | $10.45 | 823,700 | |
| $10.90 | -0.03 | -0.3% | $11.11 | $11.11 | $10.64 | 1,347,800 | |
| $10.93 | -0.59 | -5.1% | $11.56 | $11.75 | $10.89 | 1,306,900 | |
| $11.52 | -0.24 | -2.0% | $12.00 | $12.03 | $11.50 | 875,700 | |
| $11.76 | -0.11 | -0.9% | $12.37 | $12.42 | $11.72 | 881,900 | |
| $11.87 | +0.25 | +2.2% | $11.66 | $12.12 | $11.25 | 1,210,200 | |
| $11.62 | -0.18 | -1.5% | $11.92 | $12.04 | $11.42 | 1,099,600 | |
| $11.80 | -0.74 | -5.9% | $12.46 | $12.48 | $11.51 | 1,141,600 | |
| $12.54 | -0.90 | -6.7% | $13.30 | $13.45 | $12.25 | 945,200 | |
| $13.44 | +1.02 | +8.2% | $12.55 | $13.46 | $12.35 | 805,300 | |
| $12.42 | -0.14 | -1.1% | $12.80 | $12.80 | $12.28 | 939,800 | |
| $12.56 | +0.01 | +0.1% | $12.53 | $12.61 | $12.25 | 4,460,300 | |
| $12.55 | +0.32 | +2.6% | $12.55 | $12.82 | $12.43 | 1,534,800 | |
| $12.23 | -0.72 | -5.6% | $13.00 | $13.15 | $12.18 | 952,000 | |
| $12.95 | -0.16 | -1.2% | $13.07 | $13.17 | $12.45 | 1,397,100 | |
| $13.11 | +0.20 | +1.5% | $12.92 | $13.31 | $12.91 | 1,088,500 | |
| $12.91 | -0.03 | -0.2% | $13.13 | $13.50 | $12.77 | 1,257,600 | |
| $12.94 | -0.39 | -2.9% | $13.06 | $13.14 | $12.82 | 1,094,700 | |
| $13.33 | -0.60 | -4.3% | $13.76 | $13.91 | $12.95 | 1,106,800 | |
| $13.93 | -0.46 | -3.2% | $14.01 | $14.32 | $13.85 | 1,032,900 | |
| $14.39 | -0.26 | -1.8% | $14.34 | $14.74 | $14.34 | 626,900 | |
| $14.65 | +0.45 | +3.2% | $14.38 | $14.72 | $13.98 | 938,400 | |
| $14.20 | -0.07 | -0.5% | $14.38 | $14.82 | $13.87 | 619,900 | |
| $14.27 | +0.23 | +1.6% | $13.86 | $14.30 | $13.84 | 460,100 | |
| $14.04 | -0.12 | -0.8% | $14.09 | $14.16 | $13.71 | 883,000 | |
| $14.16 | -0.56 | -3.8% | $14.60 | $14.60 | $13.98 | 644,500 | |
| $14.72 | -0.01 | -0.1% | $14.74 | $15.14 | $14.62 | 508,100 | |
| $14.73 | +0.17 | +1.2% | $14.55 | $15.04 | $14.34 | 692,800 | |
| $14.56 | +0.47 | +3.3% | $14.30 | $14.83 | $14.30 | 642,200 | |
| $14.09 | -0.37 | -2.6% | $14.37 | $14.37 | $13.79 | 513,500 | |
| $14.46 | +0.13 | +0.9% | $14.52 | $14.76 | $14.38 | 473,700 | |
| $14.33 | -1.07 | -6.9% | $15.15 | $15.31 | $14.14 | 783,500 |
- Ticker
- NASDAQ:CRVS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
Latest earnings call · Nov 5, 2026
Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 6, 2026
Q2 2026 Earnings Presentation
Earnings · 26 slides
Latest news
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
Nov 9, 2026
Closed $11.37 (+0.2%) on Nov 10, 2026
Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)
Nov 5, 2026
Closed $10.54 (+8.3%) on Nov 6, 2026
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $10.54 (+8.3%) on Nov 6, 2026
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
Nov 4, 2026
Closed $10.57 (+7.5%) on Nov 4, 2026
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026
Oct 29, 2026
Closed $10.23 (-2.8%) on Oct 29, 2026
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Sep 30, 2026
Closed $10.93 (-5.1%) on Oct 1, 2026
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
Sep 3, 2026
Closed $14.65 (+3.2%) on Sep 3, 2026
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Aug 27, 2026
Closed $14.72 (-0.1%) on Aug 27, 2026
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Closed $13.92 (+0.4%) on Aug 7, 2026
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Jul 30, 2026
Closed $13.26 (+0.5%) on Jul 31, 2026
Corvus Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 126 in all · newest Nov 9, 2026 · oldest 2019
- Calls
- 18 calls with a replay · 18 with a transcript · latest Nov 5, 2026
- Decks
- 17 decks · latest Aug 6, 2026
Where Corvus Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRVS · Home listing · This page | NASDAQ | United States | USD |
| gettex:C17 | gettex | Germany | EUR |
| LS Exchange:A2AFXS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AFXS | Lang & Schwarz | Germany | EUR |
| Tradegate:C17 | Tradegate | Germany | EUR |
| BOATS:CRVS | BOATS | United States | USD |
| Dusseldorf:C17 | Dusseldorf | Germany | EUR |
| Frankfurt:C17 | Frankfurt | Germany | EUR |
| Hamburg:C17 | Hamburg | Germany | EUR |
| Munich:C17 | Munich | Germany | EUR |
| BX Swiss:C17 | BX Swiss | Switzerland | CHF |
| Stuttgart:C17 | Stuttgart | Germany | EUR |
Valuation
Price/book 3.9× against a median of 3.1×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $613.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.64
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS | US$815.7M | US$613.4M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 1.64 |
| Aktis Oncology, Inc. · NASDAQ:AKTS | US$868.0M | US$385.9M | n/a | 31.2× | n/a | 1.9× | −706.8% | 0.0× | 1.21 |
| Latigo Biotherapeutics, Inc. · NASDAQ:LTGO | US$861.9M | US$460.7M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Pharming Group NV · EURONEXT:PHARM | US$840.1M | US$766.3M | 34.4× | 2.0× | 19.8× | 2.9× | 6.3% | 0.4× | n/a |
| Odyssey Therapeutics, Inc. · NASDAQ:ODTX | US$815.2M | US$512.7M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | 1.11 |
| NATURECELL Co., Ltd. · KRX:007390 | US$803.4M | US$787.5M | n/a | 51.4× | n/a | 17.1× | −13.2% | 0.0× | n/a |
| Arbutus Biopharma Corporation · NASDAQ:ABUS | US$796.4M | US$458.9M | 3.6× | 2.5× | 3.1× | 9.3× | 121.2% | 0.0× | 1.10 |
| Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595 | US$787.5M | US$519.4M | n/a | 26.6× | n/a | 3.3× | n/a | 0.0× | n/a |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335 | US$778.7M | US$600.0M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD | US$778.1M | US$702.9M | 5.2× | 1.8× | n/a | n/a | 37.4% | n/a | 1.16 |
| Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX | US$772.7M | US$695.6M | n/a | 2.4× | n/a | n/a | −72.4% | n/a | 0.64 |
| Median of the others | US$799.9M | US$559.7M | 5.2× | 2.5× | 11.4× | 3.1× | −3.5% | 0.0× | 1.11 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 31.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.80 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Leiv Lea | Chief Financial Officer |
| Gabriel Luciano | Vice President Clinical Operations |
| Otute Akiti | Vice President, CMC |
| Suresh Mahabhashyam | Vice President Clinical Development |
| William Ben Jones | Senior Vice President, Pharmaceutical Development |
| Jeffrey Arcara | Chief Business Officer |
| Peter Thompson | CO-FOUNDER |
| Richard A Miller | CHAIRMAN and CO-FOUNDER |
Board
| Director | Role |
|---|---|
| Richard A Miller | CHAIRMAN and CO-FOUNDER |
| Andrew Chan | Board Member |
| David Moore | Board Member |
| Linda S. Grais | Board Member |
| Peter Thompson | CO-FOUNDER |
| Richard A. van den Broek | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2025 Earnings Call | Thu, Mar 12, 2026 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q1 2025 Earnings Call | Thu, May 08, 2025 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2024 Earnings Call | Tue, Mar 25, 2025 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q1 2024 Earnings Call | Mon, May 06, 2024 · 4:30 PM ET | Replay |
All 18 calls
| Call | When | Status |
|---|---|---|
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2023 Earnings Call | Tue, Mar 19, 2024 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2023 Earnings Call | Tue, Aug 08, 2023 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q1 2023 Earnings Call | Mon, May 08, 2023 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2022 Earnings Call | Tue, Mar 28, 2023 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2022 Earnings Call | Thu, Nov 03, 2022 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2021 Earnings Call | Thu, Mar 10, 2022 · 4:30 PM ET | Replay |
| Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2020 Earnings Call | Thu, Jul 30, 2020 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +8.3% |
| Q2 2026 | Aug 6, 2026 · After close | +0.4% |
| Q1 2026 | May 7, 2026 · After close | +6.6% |
| Q4 2025 | Mar 5, 2026 | −11.5% |
| Q3 2025 | Nov 4, 2025 · After close | −1.4% |
| Q2 2025 | Aug 7, 2025 · After close | +4.4% |
| Q1 2025 | May 8, 2025 · After close | +32.2% |
| Q4 2024 | Mar 17, 2025 · After close | −0.6% |
| Q3 2024 | Nov 12, 2024 · After close | +2.1% |
| Q2 2024 | Aug 6, 2024 · After close | +9.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | −12.0% |
| Q4 2023 | Mar 19, 2024 · After close | −5.6% |
| Q3 2023 | Nov 7, 2023 · After close | +1.3% |
| Q2 2023 | Aug 8, 2023 · After close | +7.9% |
| Q1 2023 | May 8, 2023 · After close | −0.4% |
| Q4 2022 | Mar 28, 2023 · After close | +11.3% |
| Q3 2022 | Nov 3, 2022 · After close | −3.4% |
| Q2 2022 | Aug 8, 2022 · After close | −9.4% |
| Q1 2022 | May 5, 2022 · After close | −4.5% |
| Q4 2021 | Mar 10, 2022 · After close | −5.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 26 slides | Aug 6, 2026 |
| Society for Investigative Dermatology 2026 | Conference | 19 slides | May 2026 |
| Technical Presentation (May 2026) | Technical | 14 slides | May 2026 |
| Q4 2025 Earnings Presentation | Earnings | 37 slides | Mar 12, 2026 |
| American Society of Hematology 2025 Annual Meeting | Conference | 16 slides | 2025 |
| Technical Presentation (2022) | Technical | 15 slides | 2022 |
| Technical Presentation (December 2020) | Technical | 13 slides | Dec 5, 2020 |
| Technical Presentation (2020) | Technical | 14 slides | Dec 4, 2020 |
| Society for Immunotherapy of Cancer (SITC) 2020 | Conference | 13 slides | November 2020 |
| Technical Presentation (2020) | Technical | 17 slides | 2020 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2019) | Technical | 18 slides | November 2019 |
| Technical Presentation (June 2019) | Technical | 17 slides | June 2019 |
| SITC 2018 (Society for Immunotherapy of Cancer Annual Meeting) | Conference | 15 slides | November 2018 |
| ASCO 2017 | Conference | 17 slides | June 2017 |
| AACR Annual Meeting 2017 | Conference | 21 slides | Apr 4, 2017 |
| Technical Presentation (2017) | Technical | 15 slides | 2017 |
| ESMO | Conference | 5 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$201.2M raised · US$22.15 a share · Jefferies +3 Dealers: Jefferies (co-lead), Goldman Sachs & Co. LLC (co-lead), Mizuho, Ladenburg Thalmann Use of proceeds: Working capital and general corporate purposes, including R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials | Jan 23, 2026 |
| Warrant exercise of common stock warrants Closed: US$31.3M raised · US$3.5 a share Buyers: Richard Miller (559,073 shares purchased for $1,956,756) Insiders: CEO Richard Miller purchased 559,073 shares for $1,956,756 through early exercise of warrants | May 8, 2025 |
| Warrant exercise of common stock warrants Announced: about US$12.7M Buyers: Samlyn Capital (exercising warrants to purchase 3,633,978 shares of common stock) | Dec 18, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Mar 22, 2016.
- Price
- US$15.00 a share
- Shares offered
- 4,700,000 shares of common stock
- Offering size
- US$70.5 million
- Underwriters' option
- Up to 705,000 more shares
- Listing
- CRVS on the Nasdaq Global Market
- Underwriters
- Credit Suisse, Cowen and Company, Guggenheim Securities, Cantor Fitzgerald & Co., BTIG · In the order on the cover
- Shares delivered
- On or about Mar 29, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 6, 2015 |
| Filed publicly | Jan 4, 2016 |
| Amended twice | Newest Mar 10, 2016 |
| Shares registered with an exchange | Mar 16, 2016 |
| Declared effective by the SEC | Mar 22, 2016 |
| Final prospectus, with the price | Mar 24, 2016 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 24, 2016 |
| EFFECT · Notice that a registration is effective | Mar 22, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Mar 21, 2016 |
| CORRESP · Letter to the SEC | Mar 18, 2016 |
| CORRESP · Letter to the SEC | Mar 18, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 16, 2016 |
| S-1/A · Registration statement, amended | Mar 10, 2016 |
| CORRESP · Letter to the SEC | Feb 8, 2016 |
| S-1/A · Registration statement, amended | Feb 8, 2016 |
| CORRESP · Letter to the SEC | Jan 4, 2016 |
All 15 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jan 4, 2016 |
| DRSLTR · Letter to the SEC with a draft | Dec 10, 2015 |
| DRS/A · Draft registration statement, amended | Dec 10, 2015 |
| UPLOAD · Letter from the SEC | Dec 7, 2015 |
| DRS · Draft registration statement | Nov 6, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 24, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 105.0K | 85.0K | 151.0K | 367.0K | 460.0K | 632.0K | 743.0K | 847.0K | 842.0K | 594.0K |
| Gross profit | -105.0K | -85.0K | -151.0K | -367.0K | -460.0K | -632.0K | -743.0K | -847.0K | -842.0K | -594.0K |
| Research and development | 33.7M | 19.4M | 16.5M | 24.5M | 29.1M | 31.8M | 38.0M | 38.6M | 46.3M | 29.4M |
| Selling, general and administrative | 9.25M | 8.16M | 6.88M | 8.10M | 9.52M | 11.9M | 10.9M | 10.6M | 10.2M | 7.62M |
| Operating income | -43.0M | -27.5M | -23.4M | -32.6M | -38.6M | -43.8M | -48.9M | -49.2M | -56.5M | -37.0M |
| Depreciation and amortization | 105.0K | 85.0K | 151.0K | 367.0K | 460.0K | 632.0K | 743.0K | 847.0K | 842.0K | 594.0K |
| EBITDA | -42.9M | -27.5M | -23.3M | -32.2M | -38.2M | -43.1M | -48.1M | -48.4M | -55.7M | -36.4M |
| Interest expense | 2.50M | 1.82M | 1.58M | 654.0K | 15.0K | 540.0K | 2.18M | 2.28M | 0 | 601.0K |
| Income before tax | -13.3M | -59.1M | -21.7M | -41.3M | -43.2M | -6.00M | -46.7M | -46.9M | -55.7M | -36.4M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -15.3M | -62.3M | -27.0M | -41.3M | -43.2M | -6.00M | -46.7M | -46.9M | -55.7M | -36.4M |
| Earnings per share, basic | -0.19 | -1.02 | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 | -1.71 | -2.72 | -2.36 |
| Earnings per share, diluted | -0.53 | -1.02 | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 | -1.71 | -2.72 | -2.36 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.58M | 8.74M | 12.6M | 13.2M | 63.5M | 16.5M | 5.15M | 39.2M | 45.1M | 5.05M |
| Short-term investments | 52.2M | 43.2M | 14.5M | 29.1M | 5.99M | 27.8M | 72.8M | 75.4M | 44.9M | 129.8M |
| Receivables | 37.0K | 75.0K | 26.0K | 588.0K | 539.0K | 86.0K | 329.0K | 337.0K | 132.0K | 365.0K |
| Inventory | -735.0K | -667.0K | -492.0K | -815.0K | -602.0K | -852.0K | -1.14M | |||
| Current assets | 58.2M | 54.4M | 28.0M | 43.7M | 71.3M | 45.3M | 79.3M | 115.6M | 91.2M | 136.0M |
| Property, plant and equipment | 220.0K | 151.0K | 236.0K | 353.0K | 451.0K | 906.0K | 1.46M | 2.18M | 2.67M | 3.25M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 71.1M | 68.9M | 45.6M | 68.2M | 109.5M | 85.5M | 83.6M | 118.2M | 94.8M | 140.2M |
| Accounts payable | 2.49M | 2.58M | 1.52M | 1.98M | 1.56M | 3.47M | 2.45M | 2.00M | 3.45M | 1.90M |
| Current liabilities | 9.38M | 35.4M | 6.87M | 10.8M | 9.69M | 12.1M | 10.2M | 7.03M | 8.97M | 5.94M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 937.0K | 1.12M | 1.37M | 2.60M | 3.65M | 2.31M | 3.19M | |||
| Total liabilities | 9.91M | 36.3M | 6.87M | 12.1M | 12.3M | 13.4M | 12.5M | 7.90M | 9.94M | 7.35M |
| Shareholders' equity | 61.2M | 32.6M | 38.7M | 56.1M | 97.2M | 72.1M | 71.1M | 110.3M | 84.8M | 132.8M |
| Shares outstanding | 74.7M | 67.9M | 49.0M | 46.6M | 46.6M | 28.4M | 28.0M | 29.3M | 21.0M | 20.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -32.8M | -25.4M | -23.9M | -27.0M | -36.7M | -34.8M | -37.3M | -41.0M | -46.2M | -27.9M |
| Capital spending | -174.0K | 0 | -34.0K | -269.0K | -5.00K | -76.0K | -25.0K | -355.0K | -266.0K | -2.20M |
| Free cash flow | -33.0M | -25.4M | -24.0M | -27.3M | -36.7M | -34.9M | -37.3M | -41.3M | -46.5M | -30.1M |
| Cash from investing | -7.80M | -27.5M | 15.5M | -23.3M | 21.6M | 44.8M | 3.25M | -30.2M | 84.8M | -42.6M |
| Cash from financing | 36.4M | 49.0M | 7.86M | 0 | 62.2M | 1.31M | 24.0K | 65.3M | 1.44M | 71.4M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 1.29M | 24.0K | 65.3M | 1.44M | 71.4M | |||||
| Change in cash | -4.16M | -3.88M | -539.0K | -50.3M | 47.0M | 11.3M | -34.0M | -5.91M | 40.1M | 945.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 22, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 13, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 13, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Mar 13, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 23, 2026 | Offer document | SEC |
| S-3MEF | Jan 21, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Jan 20, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 2, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 1, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Oct 23, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Aug 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | May 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 8, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2024 | Insider trade | SEC |
| 8-K · Current report | May 6, 2024 | Material contract | SEC |
| 8-K · Current report | May 6, 2024 | Results | SEC |
| 424B5 · Prospectus | May 3, 2024 | Offer document | SEC |
| 8-K · Current report | May 1, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 23, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Sep 6, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| 8-K · Current report | Jun 20, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 9, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2023 | Results | SEC |
| CORRESP · Letter to the SEC | May 4, 2023 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2023 | Current report | SEC |
| 4 · Change in ownership | Apr 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 3, 2023 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Mar 31, 2023 | Other filings | SEC |
| 8-K · Current report | Mar 29, 2023 | Current report | SEC |
| S-3 · Registration statement | Mar 28, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2023 | Results | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 30, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2022 | Insider trade | SEC |
| 8-K/A · Current report, amended | Nov 3, 2022 | Meeting outcome | SEC |
| 8-K · Current report | Nov 3, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 3, 2022 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2022 | Current report | SEC |
| 4 · Change in ownership | Sep 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2022 | Results | SEC |
| 4 · Change in ownership | Jun 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 6, 2022 | Insider trade | SEC |
This page holds 200 of 585 filings. Open Filings
Cap table
Built by 6ix from Corvus Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 84,353,126
- Fully diluted
- 84,353,126
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 84,353,126 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 84,353,126 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard A. van den Broek Other companies: Pulse Biosciences, Inc (Director · Since at least Aug 6, 2020); PhaseBio Pharmaceuticals Inc (Director · Feb 27, 2019 – May 19, 2023 · Past); Celldex Therapeutics, Inc. (Director · Dec 17, 2014 – Jun 8, 2016 · Past); Pharmacyclics Inc (Director · Oct 3, 2011 – May 26, 2015 · Past) | Board Member · Since at least Apr 8, 2025 |
| Terry P Gould Other companies: Icosavax Inc (Director · Jul 28, 2021 – Aug 2, 2021 · Past); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); OncoMed Pharmaceuticals Inc (Director · Jul 17, 2013 – Jun 22, 2016 · Past) | Director · Mar 22, 2016 – Jun 13, 2024 · Past |
| Jason Coloma Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026); Maze Therapeutics, Inc. (Chief Executive Officer · Since at least Jan 30, 2025) | SVP, Chief Business Officer · Jun 8, 2016 – Jun 8, 2016 · Past |
| Richard A. Miller Other companies: Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2023 · Past) | CHAIRMAN and CO-FOUNDER · Since at least Mar 22, 2016 |
| Andrew Chan | Board Member · Since at least Apr 23, 2026 |
| David Moore | Board Member · Since at least Oct 2, 2025 |
| Edith P Mitchell | Director · Jun 15, 2021 – Dec 6, 2023 · Past |
| Gabriel Luciano | Vice President Clinical Operations · Since at least Nov 4, 2026 |
| Jeffrey Arcara | Chief Business Officer · Since at least Feb 2, 2024 |
| Leiv Lea | Chief Financial Officer · Since at least Dec 6, 2023 |
All 15 people
| Person | Seat |
|---|---|
| Linda S. Grais | Board Member · Since at least Nov 4, 2026 |
| Otute Akiti | Vice President, CMC · Since at least Nov 4, 2026 |
| Peter Thompson | CO-FOUNDER · Since at least Nov 4, 2026 |
| Suresh Mahabhashyam | Vice President Clinical Development · Since at least Nov 4, 2026 |
| William Ben Jones | Senior Vice President, Pharmaceutical Development · Since at least Mar 22, 2016 |
Log in to ask 6ix AI your own questions about Corvus Pharmaceuticals, Inc.